Neil Patil
Head of Product and Platform Engineering, Chai Discovery · 1 appearance on the record.
computed by AI from the episodes · how this works → · full disclaimer →
operatorengineerfounderneilpatil.me ↗
Neil Patil is the Head of Product and Platform Engineering at Chai Discovery, working on foundation models and platforms for AI drug design. Previously, he was an early engineer and product manager at Vanta and co-founded Helping Hands Community.
17statements → 6claims → 2claims resolved → 3.65/5average certainty → 2.18/5average debate potential →
2 supported 0 partly supported 0 contradicted 4 not checkable as stated how the 6 claims stand · each chip opens the sources
1 prediction · 5 assertions · 2 opinions · 3 insights · 6 disclosures · every statement was checked. The prediction and assertions are the 6 claims: statements the public record can support or contradict. 2 are resolved, and 4 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.
The record, in short
What the tape says about how Neil argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.
Their most notable supported claim
Patil: Chai-2 demonstrated precise antibody-based GPCR agonist activity
“For example, in CHI-II, we showed like GPCR agonist activity, right? Where you can really hit the switch on a, you know, on a cell doorbell protein, so to speak, right? In a very precise way. Very, very, very hard to do that with antibodies if you can't be tha…”
Everything Neil Patil said on Latent Space that made the record, most notable first. Filter by type, assessment or year in the ledger →
Patil: Enterprise cybersecurity buyers are surprisingly non-technical and unsophisticated
“I come from a cybersecurity background or, you know, have worked on security products before and those were dark, dark years because you spend a lot of your time actually selling to people who are surprisingly not that technical. You think cybersecurity people…”
Patil: Biomolecular AI models will be as massive and impactful as LLMs
“And, you know, I think this class of models is going to be like just as big, just as impactful as LLMs, but it's almost like the compute market, like kind of doesn't realize that yet, both in the capacity sense, but also in like the software stack sense.”
Patil: Chai operates as a neutral software factory for medicines
“There's a lot of bio companies, AI for bio companies that are like making their own drugs. We really don't see ourselves that way, right? We see ourselves as almost a neutral software factory. For making medicines.”
Patil: Generative models enable atom-level precise antibody epitope design
“And I think, like, one of the things that's really exciting about where we're getting to with some of these models is we can start to get that precise, right? Epitope, right? Meaning like binding spot, right? A very specific set of atoms to have the antibody g…”
Patil: Chai-2 crossed the performance threshold for antibody design last year
“The ultimate goal here is to design medicines, right, and design new molecules, and I think CHI-2 really crossed the threshold of performance for doing that with antibodies a year ago.”
Patil: Enterprise software lifespans have shrunk from 20 years to one year
“Like maybe you'd have built software that was supposed to last like 20 years. Now it's supposed to last maybe one year, but it is the bridge to deliver value and kind of enable the research that then gets you to the next thing.”
Patil: Chai-2 demonstrated precise antibody-based GPCR agonist activity
“For example, in CHI-II, we showed like GPCR agonist activity, right? Where you can really hit the switch on a, you know, on a cell doorbell protein, so to speak, right? In a very precise way. Very, very, very hard to do that with antibodies if you can't be tha…”
Patil: Hyperscalers and top AI labs buy 95% of top-tier GPUs
“The hyperscalers and the, you know, the biggest the biggest AI labs are buying 95 plus percent of it, right? And then you kind of have the startups, like, fighting over the scraps.”
Patil: Closed frontier models capture the majority of market value
“And actually, if you look at the amount of value captured, it's actually the closed source frontier models. You know, the whole pie is growing, but it's growing so fast that even as the open source models like share expands, the frontier models are still able …”
Patil: GLP-1 drug revenue recently exceeded all AI labs combined
“Yeah, I mean, I think up until I think three months ago, right, GLP one's like total revenue was more than all of the AI labs put together.”
Patil: Chai is raising capital to train more general generative models
“Like a lot of the money that we're raising now will let us train bigger models that can maybe be even more general and start to account for even more things at the same time, right?”
Patil: Modern structure prediction models achieve sub-angstrom experimental accuracy
“We're getting the point now where these structure prediction models are within, you know, a few angstroms or less of the actual atomic positions that you validate.”
Patil: Chai runs wet-lab experiments only to validate its models
“We don't care about going and developing those drugs. Like we just do that in service of validating and making our models better.”
Patil: Chai fine-tunes specialized foundation models for biopharma enterprise partners
“A lot of these deals you know, and this is all public, right? We are working with them to, you know train or fine tune a version of our model for them.”
Patil: Biology is rapidly transitioning into a precision CAD engineering discipline
“You start to get to the point where now you can declaratively precision engineer what you want, rather than betting on, you know, nature or trial and error to get you there. And I think that Look, we had the same thing happen in software where you can write co…”
Patil: Eli Lilly was an early design partner for Chai's V1
“We'd been working with you know or talking to Eli Lilly and, you know, they were, you know one of the first partners to really work with us closely on that kind of you know, it made that V one of that that design suite, right. That you can use to engineer some…”
Patil: Chai Discovery maintains a total company headcount of 30 people
“We're only 30 people. And that's because everyone we hire onto the research team or the engineering team, you know, especially now that they're in some ways like very empowered with AI, A lot of it is just, like, allocating, you know, their attention into the …”
Appearances (1)
| Episode | Date | Speaking time |
|---|---|---|
| 🔬They Thought the Model Was Broken — Matt McPartlon & Neil Patil, Chai Discovery | Aug 11, 2026 | 34m |